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Abstract 
 Within pigment-producing cells known as melanocytes, the transcription factor MITF is 
intimately involved in regulating genes associated with cell cycle maintenance and melanocyte 
differentiation. Research, however, has provided conflicting results on the relationship between 
the expression levels of MITF and melanocyte cell fate. To complicate matters, two splice 
variants of MITF exist, differing by only 18 base pairs. These variants have been observed at 
variable levels of expression in melanocyte and melanoma cells, raising the question as to their 
functional purpose. Building upon previous research by the Leachman/Cassidy lab that identified 
the redox sensitivity of MITF while additionally establishing a novel relationship between the 
antioxidant selenoprotein Thioredoxin Reductase 1 (TR1) and pigment synthesis, this work seeks 
to examine the redox sensitivity and function of the MITF splice variants. 
Introduction  
Melanocytes are specialized cells located primarily within the basal layer of the 
epidermis, where they synthesize photoprotective pigments known as melanin (Yamaguchi et al., 
2007). Melanin is a polymer that absorbs ultraviolet (UV) radiation, protecting surrounding 
keratinocytes from UV-induced DNA damage by diffusing light energy (Nguyen & Fisher, 
2019). Excess UV-induced DNA damage, however, can contribute to the incidence of 
melanoma, the cancer which results from the aberrant growth and proliferation of melanocytes. 
While melanoma accounts for only 1% of all skin cancer cases, it is responsible for the majority 
of skin cancer related deaths (Institute, 2020). Notably, melanocytes are derived from neural 
crest cells, a heritage that likely influences the ease of epidermal to mesenchymal transition and 
thus enables aggressive metastasis (Larribère & Utikal, 2019). Several genetic mutations are 
associated with increased melanoma risk, including the oncogenic BRAFV600E substitution, and 
mutations in the CDKN2A tumor suppressor locus (Hodis et al., 2012; Potrony et al., 2015). 
Although there are therapeutic treatments currently available, both intrinsic and developed drug 
resistance is a hallmark of melanoma (Helmbach et al., 2001), prompting ongoing research into 
the regulatory mechanisms of melanocyte and melanoma cell fate. 
The microphthalmia associated transcription factor (MITF) is known as the “master 
regulator” of melanocyte differentiation and proliferation pathways (Hemesath et al., 1994; 
Kawakami & Fisher, 2017). This transcription factor has multiple tissue-specific isoforms that 
arise from different enhancer-promoters, resulting in the variable identity of exon 1 (Fuse et al., 
1999). However, only the m-isoform is expressed in select cells of neural crest origin and of 
those, most notably in melanocytes, where MITF regulates the expression of enzymes 
responsible for melanin synthesis (M. Murakami et al., 2007). Additionally MITF serves as a 
transcriptional activator of essential cell survival genes such as MET and BCL2 (Beuret et al., 
2007; McGill et al., 2002) while also regulating the expression of CDKN2A, which inhibits the 
cell cycle and thus maintains cell differentiation (Loercher et al., 2005). These connections to 
cell cycle regulation have thus made MITF a suspect of oncogenic involvement. 
 MITF derives its name from the phenotype resulting from mutation of the murine Mi 
locus. This phenotype consists of the complete loss of melanocytes as well as the development of 
small eyes (microphthalmia) (Kawakami & Fisher, 2017). Mutations in the human MITF 
homolog result in variable expression of Waardenburg syndrome type II, characterized by 
abnormal pigmentation, hearing loss, and microphthalmia (Tassabehjil et al., 1994). This 
 
 
transcription factor is a basic helix-loop-helix leucine zipper containing a transactivation domain 
which binds the canonical E-box motif, as well as an extended E-box termed the “m-box” 
(Hartman & Czyz, 2015). In its active conformation, MITF dimerizes with itself or other bHLH- 
Zip transcription factors, specifically TFE3, TFEB, or TFEC (Hemesath et al., 1994).  
 MITF activation is regulated during development by several lineage-specific factors. 
Notably, Sox10 and Pax3 mediate melanocyte cell survival through MITF activation, acting in 
synergy to promote transcription (Wellbrock & Arozarena, 2015). The Wnt pathway also alters 
MITF expression via β-catenin binding with LEF1, which activates the MITF promoter, an 
activity shown to regulate both differentiation and melanocyte growth (Chien et al., 2009; 
Eichhoff et al., 2011; Widlund et al., 2002). Intriguingly, MITF has also been shown to interact 
with LEF1 to modulate its own expression (Saito et al., 2002).  
Canonically, MITF is involved in melanogenesis, the skin’s major defense system against 
ultraviolet radiation (Nguyen & Fisher, 2019).  UV-induced DNA damage within keratinocytes 
activates transcription of POMC via p53. POMC is subsequently post-translationally cleaved into 
α-MSH, the signaling molecule for MC1R, a receptor located on the melanocyte plasma 
membrane (Hsiao & Fisher, 2014). Activation of MC1R triggers a cAMP signaling cascade that 
enables CREB binding to the MITF promoter, activating transcription of MITF (Yamaguchi et 
al., 2007). Once translated, MITF activates the expression of Tyrosinase (TYR), Tyrosinase 
Related Protein 1 (TYRP1), and Dopachrome Tautomerase (DCT) - enzymes essential for 
pigment biosynthesis (Fang, 2002; Jiao et al., 2004; Yasumoto et al., 1995). Additionally, MITF 
regulates the expression of PMEL, a melanosome structural protein that enables melanin 
deposition, and MLANA, a melanocyte-specific membrane protein (Sitaram & Marks, 2012). 
 MITF undergoes an array of post translational modifications that alter its activity as a 
transcriptional regulator (Wellbrock & Arozarena, 2015). Principally, MITF is phosphorylated at 
serine 73 via MAPK, a modification shown to recruit p300, a histone acetyltransferase, which 
promotes melanocyte cell growth in a MITF-dependent fashion (Kim et al., 2019; Price et al., 
1998). Phosphorylation of MITF was shown to increase affinity for the tyrosinase promoter, 
leading to speculation that phosphorylation could also modulate the transcriptional regulation of 
additional MITF target genes (Hemesath et al., 1998). Surprisingly, this modification was also 
shown to enable ubiquitin-mediated proteolysis, indicating tightly regulated post-translational 
control of MITF function (Wu et al., 2000). MITF is also targeted by SUMOylation at two lysine 
residues, a modification shown to repress its transcriptional activity for some but not all target 
promoters (H. Murakami & Arnheiter, 2005). A germline mutation that affects the SUMO 
binding sequence in MITF has additionally been identified in patients with melanoma (Bertolotto 
et al., 2011).  
 In addition to the known mechanisms of transcriptional and post-translational control, 
two splice variants of MITF have been observed at variable expression levels in melanocyte and 
melanoma cell lines (Primot et al., 2009). These splice variants differ by an alternative splice 
acceptor in exon 6 that controls for the presence or absence (designated + or -18) of 18 
nucleotides upstream of the DNA binding domain (Hodgkinson et al., 1993; Steingrimsson et al., 
1994). These 18 nucleotides code for the amino acid sequence ACIFPT (Tachibana et al., 1994). 
Although the function of these variants is currently unknown, Primot et al found that the -18 
isoform predominates in cultured melanoma cell lines, and variant expression is modulated by 
MEK inhibition (Primot et al., 2009). Additionally, MITF +18 expression was shown to elicit 
 
 
transcription of tyrosinase more efficiently, whereas other research found that this isoform has an 
inhibitory effect on DNA synthesis, and subsequently cell proliferation (Bismuth et al., 2005; M. 
Murakami et al., 2007). 
 Our investigation of MITF function coincides with an inquiry of melanocyte response to 
oxidative stress. Melanocyte cells are exposed to oxidative stress from a variety of sources, 
including the melanin synthesis process which generates hydrogen peroxide, and UV radiation, 
which induces reactive oxygen species (ROS) including superoxide anion (Meyskens et al., 
2001). In general, oxidative stress incites a distinct cellular response which can be alleviated by 
antioxidant proteins, such as the Thioredoxin/thioredoxin reductase and glutathione/glutaredoxin 
redox systems, as well as additional antioxidant programs that are transcriptionally controlled by 
Nrf2 and the redox sensor APE-1 (Liu et al., 2009; Tonelli et al., 2018). However, melanoma 
cells have been reported to contain higher levels of ROS than normal melanocytes (Policastro et 
al., 2009). While increased oxidative stress is expected to increase the DNA mutational load and 
subsequent cancer potentiation of a cell, such stress may additionally dysregulate redox-mediated 
cell signaling pathways. Consequently, it is suggested that alterations in the redox state of 
melanocytes are involved in the pathogenesis of melanoma (Meyskens et al., 2001). 
 Previous research by Cassidy et al found a positive correlation between melanoma stage 
and Thioredoxin reductase 1 (TR1) expression, suggesting that upregulation of this antioxidant 
may be a factor in melanoma development (Cassidy et al., 2015). Subsequently, while further 
investigating the relationship between TR1 expression and melanocyte behavior, the 
Leachman/Cassidy lab found that melanin was significantly reduced after knocking down TR1 in 
immortalized melanocytes. This turned attention towards the regulator of pigment biosynthesis - 
MITF.  
To understand the role of TR1 in pigmentation, the Leachman/Cassidy lab first examined 
the effects of redox stress on the network of cellular antioxidants, including TR1, its substrate 
Thioredoxin (TRX), and peroxiredoxin 1 (PRX1), a thiol oxidoreductase known to interact with 
TRX via disulfide exchange. To investigate these proteins under redox stress, cells were treated 
with varying concentrations of hydrogen peroxide. Following hydrogen peroxide treatment, cells 
were supplemented with N-ethylmaleimide (NEM) to covalently modify reduced thiols and 
prevent oxidized artifacts, thereby capturing the oxidation states of cellular proteins (García-
Santamarina et al., 2014; Hansen & Winther, 2009). Cell lysates were then fractionated by non-
reducing SDS-PAGE. By this method, proteins that engage in disulfide bonds with other proteins 
are anticipated to appear at higher molecular weights on a western blot, indicative of protein 
complexes (Stöcker et al., 2018). To our surprise, probing these blots for MITF showed 
unexpected high molecular weight species in melanocytes treated with hydrogen peroxide (figure 
1A). Additionally, when the same lysates were run under reducing conditions, MITF was 
restored to its expected weight of approximately 54 kD, consistent with the behavior of transient 
redox-sensitive complexes (Figure 1B). These experiments revealed that MITF is capable of 
forming disulfide linked conjugates under oxidative stress, suggesting that MITF serves a redox-
mediated function within the cell. Combined with the observation that pigment synthesis is 
reduced in TR1 knockdown cells, these results indicate that MITF responds to TR1 regulation, 
potentially in a direct or indirect redox-dependent fashion. Together, these findings point towards 
a redox associated role for MITF in melanocyte biology and the development of melanoma.  
 
 
  Heterogeneous expression of MITF in Melanoma cells has complicated the distinction 
between MITF and cell fate (Ennen et al., 2015; Goodall et al., 2008). A “rheostat model” has 
been suggested for MITF, where low levels of expression correspond to senescence or invasive 
properties, and higher expression to proliferation and differentiation tendencies (Goding, 2011). 
In line with this model, we hypothesize that a balance between MITF variant expression is 
involved in maintaining the associated differentiation and proliferation pathways in normal 
melanocytes. With the observation that MITF is sensitive to hydrogen peroxide and additional 
evidence that its transcriptional targets are impacted by inhibition of endogenous redox protein 
(Kline et al., n.d.) we suggest MITF undergoes a redox-mediated post translational modification 
that affects its activity within the cell, thereby attenuating transcriptional targets in accordance 
with cellular redox conditions. Furthermore, because the 18 base pairs retained by the +18 
isoform encode an additional cysteine residue capable of oxidation, we hypothesize the splice 
variants may be differentially responsive to redox conditions, thus affecting their expression, 
protein interactions, and/or target genes. Cumulatively, a change in cellular redox state may 
therefore affect the expression and functional response of the MITF variants, leading to a 
modulated cellular response that may direct melanocytes towards a proliferative, cancerous 
phenotype.  
 To investigate this hypothesis, we designed MITF variant-specific expression vectors and 
transfected multiple cell lines to optimize protein expression. Transfected cells were treated with 
hydrogen peroxide to induce oxidative stress, and protein was extracted and analyzed under 
reducing and non-reducing conditions. The final expression constructs are equipped with dual 
tags, enabling co-immunoprecipitation of MITF with any binding partners, and their 
identification by mass spectrometry.  This will allow us to assess whether the MITF variants 
interact with different proteins, potentially in a redox-dependent fashion. While this work 
represents only the initial stages of our intended investigation of MITF variant activity, our 
preliminary data corroborates earlier findings, and will enable further examination of the 
functional characteristics of MITF splice variants. 
 
 
 
 
 
 
 
 
 
 
 
 
Methods and Results 
Our initial goal was to isolate expression of the MITF + and – 18 bp variants. We 
constructed affinity tagged MITF expression vectors and transfected various cell lines that do not 
endogenously express the melanocyte-specific MITF isoform (MITF-m). The MITF - 18 
expression plasmid was purchased from Addgene (pCMV Tag4a-MITF-M (wt), #33151). This 
plasmid encodes a carboxyl terminal flag tag, as well as a neomycin resistance gene. The MITF 
+ 18 variant was constructed by overlap extension PCR to integrate the missing 18 bp sequence 
into the pCMV-Tag4a plasmid. We primarily transfected Hela cells, as the endogenous MITF 
expression has previously been characterized in this cell line. HeLa cells express the MITF-A, C 
and H isoforms, but do not express the m isoform (Fuse et al., 1999; Primot et al., 2009). We 
conveniently found that the MITF D9 antibody (Santacruz, sc-515925) although advertised as a 
MITF-m specific antibody, additionally detects the MITF-A isoform, confirmed by both western 
blot (Supplemental Figure 1, Appendix) and examination of the D9 epitope sequence. In contrast 
the MITF C5 antibody (Millipore Sigma, MAB3747-I) appears specific to the MITF-m isoform. 
Figure 1. Western blot of PIG1 melanocytes with hydrogen peroxide treatment courtesy of Dr. Chelsey 
Kline, from her paper currently under review. TR1lo cells stably express a siRNA targeting Thioredoxin 
reductase 1, while TR1high cells express a control siRNA that does not target a eukaryotic transcript. Cells 
were subsequently treated with a 1 min burst of hydrogen peroxide at different concentrations, followed by 
treatment with 100 mM NEM to covalently modify reduced thiols. a) Protein lysate run on a non-reducing gel 
showcases MITF at high molecular weights (MITF-S-S-X) as well as the anticipated monomeric weight of 54 
kD. b) Running the same lysates under reducing conditions shows that MITF is restored to its 
anticipated molecular weight of approximately 54 kD upon reduction by BME. A similar response to 
hydrogen peroxide is observed by peroxiredoxin 1 (PRX1), which dimerizes under non-reducing conditions 
(PRX1-S2, PRX1-S-S2). 
 
 
 
The application of these two antibodies subsequently allowed us to compare the protein levels 
from our expression vectors against endogenous MITF levels in HeLa cells. 
HeLa cells (ATCC, CCL-2) were transfected using both lipofectamine and Neon 
electroporation (ThermoFisher) to determine the best method of transfection. Although HeLa 
cells are considered an easily-transfectable cell line, we experienced inconsistent protein 
expression using either transfection method. Geneticin aminoglycoside antibiotic (Life 
Technologies, #11811023) was used to select for stable expression of MITF following 
transfection, however the selection process appeared to affect cell viability, further contributing 
to low protein yields and preventing establishment of stable cell lines. While MITF expressing 
non-melanocyte cell lines have been generated by other labs, reviewed literature indicates MITF 
was only transiently expressed in such experiments. Therefore, we hypothesize that non-
melanocyte cells do not have a favorable response to stable expression of the melanocyte specific 
MITF isoform. Additionally, we hypothesized the carboxyl tag itself could be inhibiting protein 
detection, given the differences observed when probing the same samples with anti-MITF (C5) 
and anti-flag antibodies (Figure 2). Consequently, we later found literature that indicates MITF is 
cleaved by caspases to produce a 45 kD amino terminal fragment (Larribere et al., 2005). Such 
cleavage by caspases would explain the differences in detection between anti-MITF (C5) and 
anti-flag antibodies on the same membranes, as cleavage of the carboxyl terminus would result 
in loss of the flag tag. Typically, the melanocyte specific MITF isoform is observed around 54kD 
and 60kD on western blots, the higher molecular weight species being attributed to the 
phosphorylated form of MITF (Hemesath et al., 1998). 
 
 
 
 
 
 
 
Figure 2. Western blot of HeLa cells transfected with pCMV-Tag4a MITF-m variant plasmids. 
Replicate membranes were blotted with anti-flag and anti-MITF C5 antibodies to compare detection 
between the two antibodies. a) The anti-flag antibody shows negligible protein expression. b) Results from 
the C5 antibody indicate MITF expression, however the -18 variant shows greater expression in 
comparison to the +18 variant. Furthermore, an approximately 45 kD band is recognized by the C5, but not 
the anti-flag antibody, supporting its identification as an amino terminal fragment of MITF, produced by 
caspase cleavage. 
 
 
 
Construction and Expression of N-terminal Flag-tagged MITF 
To test the hypothesis that the C-terminal tag affects expression of MITF, we constructed 
N-terminal flag-tagged expression vectors. The pCMV-Tag2b vector, encoding an amino 
terminal flag tag, was a generous gift from Dr. Ping Xing, Oregon Health & Science University. 
The MITF variant inserts were isolated from the previous pCMV-Tag4a vectors by digesting 
with EcoRI and HindIII restriction enzymes. The pCMV-Tag2B vector was additionally digested 
and treated with calf intestine alkaline phosphatase, and both inserts and vector were isolated by 
gel electrophoresis on 1% TAE agarose gel. The DNA fragments were excised from the gel and 
purified using the QIAquick gel extraction kit (Qiagen, #28704). Overnight ligation at 16°C was 
completed using T4 DNA ligase (ThermoFisher, # 15224017) at a 3:1 insert to vector molar 
ratio. One Shot TOP10 E. coli (Thermofisher, # C404003) were transformed with the ligated 
reaction according to manufacturer’s recommendations. The transformations were plated on LB 
plates with kanamycin (50µg/ml), and isolated colonies were selected and grown in 100 mL 
volumes of LB liquid culture. Plasmids were then purified from the bacterial cultures using the 
Qiagen Endofree plasmid maxi kit (Qiagen, #12362), quantified using a Biotek Synergy H1 
microplate reader, and sequenced (Vollum DNA sequencing Core, OHSU).  
Transfection with the pCMV-Tag2b MITF variant plasmids was performed using 
Lipofectamine 3000 lipid reagent (Fisher Scientific, L3000-08). Lipofectamine 3000 was used 
according to manufacturer's recommendations, with Optimem serum free media, P3000 reagent, 
and 2.5 µg plasmid. Solutions were added to 6-well plates with 250,000 HeLa cells/well. 
Twenty-four hours post transfection, cell media was removed and replaced with either 100µM 
H2O2 or PBS for 1 minute. Treatment was then removed and replaced with 100 mM NEM in 
PBS and incubated for 5 minutes on ice. Cells were subsequently harvested in lysis buffer (40 
mM HEPES- pH7.5, 50 mM NaCl, 1 mM EDTA, 1% Triton X-100) with 100 mM NEM. 
Lysates were incubated for 1 hour at 37°C, sonicated, and centrifuged. Protein lysates were 
divided into reducing and non-reducing aliquots, whereby reducing samples were heated for 5 
minutes at 95℃ in NuPAGE loading buffer (Invitrogen, NP0007) with 𝛽-Mercapthoethanol 
(BME) at 1% final concentration. Non-reducing samples were heated in NuPAGE buffer only. 
Protein lysates were quantified by BCA protein assay, and 7 ug of protein per sample was run on 
4-12% bis-Tris SDS-PAGE gel for 90 minutes at 100 volts. The gel was transferred to a 0.45 µm 
PVDF membrane on ice for 60 minutes at 30 volts. Membranes were then blocked in 5% non-fat 
dried milk in Tris-buffered saline overnight. Each membrane was blotted with anti-MITF C5, 
anti-Flag (Sigma Aldrich, # F1804), and β-actin (Cell Signaling, # F1804) with complementary 
secondary antibodies conjugated to horseradish peroxidase (Abcam, ab6789 and ab6721). The 
membranes were subsequently exposed with chemiluminescent reagent (ThermoFisher, #34076) 
and imaged. 
 Use of Lipofectamine 3000 reagent was found to increase transfection efficiency over 
Neon Electroporation. A time course study of protein expression indicated that 24 hours post 
transfection was optimum, having high expression levels without compromising cell viability. 
Application of NEM following hydrogen peroxide treatment preserved disulfide conjugated 
proteins induced by redox stress, and enabled visualization of protein conjugates on non-
reducing gels (Figure 3). MITF was in fact observed at higher molecular weights in hydrogen 
peroxide treatment groups on non-reducing gels (Figure 3a), as previously described by Kline et 
al. In contrast, running the same protein samples under reducing conditions restores MITF to its 
 
 
monomeric molecular weight of 54 kD (Figure 3b). On additional reducing gels, MITF 
expression was also observed around 45kD (Figure 4). This observation is consistent with the 
reports of MITF cleavage by Lariberre et al, which produces a 45kD N-terminal MITF fragment 
(Larribere et al., 2005). Because we are hoping to identify binding partners of MITF through 
immunoprecipitation and mass spectrometry, cleavage of the protein could compromise efficient 
isolation of the entire polypeptide.  
 
 
 
 
 
 
 
Figure 4. Hela cells transfected with N-terminal flag-tagged MITF variants, run under reducing 
conditions. Twenty-four hours after transfection with lipofectamine 3000 reagent, MITF is observed at two 
molecular weights. Probing with either C5 antibody (a) or anti-Flag antibody (b) indicates the presence of 
an MITF fragment of approximately 45 kD.  
 
Figure 3. Western blot of HeLa cells transfected with N-terminal flag-tagged MITF variants and 
treated with hydrogen peroxide. Under non-reducing conditions, MITF appears at high molecular 
weights in hydrogen peroxide treatment groups only (MITF-S-S-X), whereas MITF in untreated cells is 
observed at its anticipated molecular weight between 50-65 kD (figure 4A). Under reducing conditions, 
MITF is restored to its anticipated molecular weight (figure 4B) as expected of transient, disulfide linked 
proteins. Probing these blots for Peroxiredoxin 1 (Prx1), a protein known to dimerize via disulfide bonds 
(Prx12), shows a similar pattern of high molecular weight species on non-reducing gel. 
 
 
 
 
Construction and expression of dual-tagged MITF transfection vector 
 To ensure isolation of the intact MITF polypeptide during immunoprecipitation, we 
designed a dual-tagged expression vector that will enable affinity purification with 2 different 
antibodies. A pCMV6-AC-3HA plasmid (Origene, PS100067) encoding a triple hemagglutinin 
(HA) carboxyl tag was utilized as the transfection vector. A BsiWI restriction site was 
substituted into the pCMV-Tag2B MITF variant plasmids using overlap extension PCR. By this 
method, the MITF variant sequences and amino-terminal flag tag could be isolated from the 
Tag2B plasmids by restriction digest. The pCMV-Tag2B MITF variant plasmids were amplified 
with CMV-F/BsiWI-R and BsiWI-F/T7-F primer pairs (Table 1, appendix) using Phusion Flash 
polymerase (Thermofisher, F548S). The reactions were purified using the Purelink PCR 
purification kit (Invitrogen, K310001), then the reaction products were amplified together using 
the CMV-F/T7-F primer pair. The PCR product was again purified, then digested alongside the 
pCMV6-AC-3HA vector using BmtI and BsiWi high fidelity restriction enzymes (NEB, R3658S 
and R3553S). The vector was treated with calf intestine alkaline phosphatase, then both inserts 
and vector were isolated by gel electrophoresis on 1% TAE agarose gel. After gel extraction and 
purification, insert and vector were mixed at a 3:1 molar ratio, treated with T4 DNA ligase, then 
incubated for 1 hour at room temperature. Transformation, plasmid purification, and sequencing 
were performed as previously described.  
 M14-/- and WT melanoma cells were transfected with the dual-tagged MITF expression 
vectors using lipofectamine 3000 reagent as previously described. The M14-/- cell line is a TR1 
knockout generated by Dr. Chelsey Kline using CRISPR/Cas9 technology. RNAseq analysis of 
these cells indicates that the melanocyte specific MITF isoform is no longer expressed in these 
cells following TR1 knockout (Kline et al., n.d.). Given that WT M14 cells endogenously 
express the melanocyte specific MITF isoform, we anticipated these cells would more readily 
express MITF variant constructs than HeLa cells. A hydrogen peroxide assay and SDS-PAGE 
were run as previously described, with protein lysates fractionated under reducing and non-
reducing conditions. Confirming earlier findings, both MITF variants treated with hydrogen 
peroxide were observed at high molecular weights on non-reducing gels (Figure 5b). In 
comparison, MITF was only observed at its monomeric molecular weight of 54 kD in control 
groups without hydrogen peroxide treatment (Figure 5a).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5. M14 cells transfected with dual-tagged MITF variant plasmids.                                           
a) In control cell lysates fractionated under non-reducing conditions, MITF is primarily observed at its 
monomeric molecular weight, between 50-65kD. b) Following treatment with hydrogen peroxide, MITF 
is observed at high molecular weights (MITF-S-S-X) under non-reducing conditions. c, d) When the 
same cell lysates are run under reducing conditions, MITF is observed only at its monomeric molecular 
weight, regardless of treatment group.  The restoration of MITF to its monomeric molecular weight 
following reduction by BME is indicative of transient, disulfide-linked protein conjugates. Surprisingly, 
MITF was not detected in M14 WT cells at this exposure, indicating that expression of the MITF 
constructs is much higher than endogenous levels of MITF in M14 cells. 
 
 
 
Discussion 
 Redox modifications have been implicated in the regulation of multiple transcription 
factors and signaling pathways, primarily those responsible for regulating antioxidant programs 
at the transcriptional level (García-Santamarina et al., 2014). For example, the transcription 
factor NF-κB has been identified as redox responsive, interacting with TRX to enable DNA 
binding activity (Hayashi et al., 1993; Toledano et al., 1993). Similarly, the activity of the Pax8 
transcription factor is dependent on redox state and inhibited by glutathionylation (Cao et al., 
2005; Codutti et al., 2008). The redox effector protein APE-1 (Ref-1) also co-activates 
transcription factors via disulfide exchange, activating both NF-κB and Hif1-⍺, a subunit of the 
oxygen homeostasis regulator Hif1 (Huang et al., 1996; Tell et al., 2009). Intriguingly, MITF 
interacts with some of these redox-sensitive proteins. MITF has been shown to upregulate APE-1 
expression in response to cellular redox stress, while MITF additionally binds the Hif1-⍺ 
promoter and strongly stimulates its transcriptional activity (Buscà et al., 2005; Liu et al., 2009). 
These MITF targets implicate MITF as a component of the cellular redox response. 
Our work investigates a previously unknown aspect of MITF involvement in the cellular 
redox response. Previous work by the Leachman/Cassidy lab found that knockdown of the 
antioxidant TR1 results in reduced pigment synthesis in melanocytes, suggesting a novel 
association between the TR1antioxidant network and the pigment synthesis pathway. Upon 
examination of the cellular effects of TR1 knockdown under hydrogen peroxide-induced redox 
stress, MITF was observed to form disulfide linked conjugates after fractionation of cell lysates 
by non-reducing SDS-PAGE, illustrating its redox sensitivity. Together these findings support 
the hypothesis that MITF may be regulated by TR1 in a redox-dependent fashion, altering its 
transcriptional activity. While we suggest a discrete function for MITF redox sensitivity, 
additional research must be undertaken to delineate the effects of redox modification on MITF 
regulated genes or protein targets. In addition to the proposed redox-dependent functionality of 
MITF, we hypothesize the two MITF splice variants respond differently to redox regulation, 
according to the presence or absence of an additional cysteine residue. These variants may serve 
different functions in the cell, modulating cell fate according to cellular redox conditions.  
To investigate the redox sensitivity of the MITF variants in vivo, we constructed affinity 
tagged MITF variant vectors and transfected mutant melanoma and non-melanocyte cell lines. 
Treatment of cells with hydrogen peroxide followed by free thiol quenching with NEM allowed 
us to identify high molecular weight MITF species on non-reducing SDS-PAGE that were not 
present under reducing conditions. This is indicative of transient, disulfide-linked protein 
conjugates. However, both variants engaged in these redox-mediated conjugates, leading us to 
conclude that analysis of MITF by western blots cannot distinguish differences in redox activity 
between the two variants. Given that the +18 variant retains an additional cysteine residue, it is 
plausible this variant responds more readily to redox regulation. In this fashion, the -18 variant 
could be less sensitive to cellular redox conditions, and its overexpression could serve as a 
mechanism of cellular escape from redox regulation, potentially driving a cancerous phenotype. 
To delineate these theoretical functions, we intend to perform co-immunoprecipitation of the 
MITF variants and assess interacting proteins by mass spectrometry. This will help elucidate 
whether the splice variants interact with different proteins in a redox-mediated fashion, 
contributing to differential activation of downstream targets. 
 
 
Given the endogenous redox stress within melanocytes and reported increase in ROS in 
melanomas, an explicit response to ROS is required to maintain melanocyte homeostasis. 
Although MITF redox sensitivity has only been preliminarily identified, confirming this novel 
mechanism of MITF regulation and its effect on cellular phenotype will help elucidate the multi-
faceted role of MITF in melanocyte cell fate. MITF is regulated by multiple activation pathways 
and post translational modifications, contributing to its range of expression levels in melanocyte 
and melanoma cells. Although levels of MITF expression have been linked to a spectrum of 
cellular behavior, the implications of MITF splice variant expression have not been extensively 
investigated. While we are exploring the role of these splice variants in the melanocyte specific 
MITF isoform, these variants have been additionally reported in other MITF isoforms (M. 
Murakami et al., 2007). Differential response of the splice variants to redox regulation could 
serve as an additional mechanism of regulation in tissues that express these other MITF 
isoforms. Consequently, understanding the comparative function of the MITF splice variants will 
illuminate their role in cell fate, contributing to our understanding of cellular regulation in 
melanocytes and melanomas.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
Table 1. Primers used for overlap-extension PCR  
CMV-F 5’ TAGTCATCGCTATTACCATGGTGATGC 
BsiWI-F 5’ GCACACTTGTCGTACGATCGATACCG  
BsiWI-R 5’ CGGTATCGATCGTACGACAAGTGTGC  
T7-F 5’ CGAGTGAATTGTAATACGACTCACTATAGGG  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1. Comparison of C5 and D9 antibodies in M14-/- and WT cells.                 
The anti-MITF C5 and D9 antibodies show differences in MITF detection between M14 WT and TR1 
knockout (MT) cells. C5 fails to identify MITF expression in two knockout lines (Ck3-98-8(5) and 
(11)). RNAseq analysis confirms these lines lack MITF-m expression but retain MITF-A expression. 
Additional analysis of the D9 epitope sequence confirms it is found in both the MITF-A and m 
isoforms, explaining why D9 detects MITF in those cells where MITF-m is not expressed. 
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